## Elizabeth R Brown

## List of Publications by Citations

Source: https://exaly.com/author-pdf/9233689/elizabeth-r-brown-publications-by-citations.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

1,290 15 41 35 h-index g-index citations papers 8.2 2,066 4.61 52 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
41	Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2121-2132	59.2	480
40	Vaccine optimization for COVID-19: Who to vaccinate first?. Science Advances, 2020, 7,	14.3	138
39	Coronary calcium coverage score: determination, correlates, and predictive accuracy in the Multi-Ethnic Study of Atherosclerosis. <i>Radiology</i> , <b>2008</b> , 247, 669-75	20.5	78
38	Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 326, 46-55	27.4	77
37	Vaccine optimization for COVID-19: who to vaccinate first? <b>2020</b> ,		59
36	Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2016</b> , 73, 606-608	3.1	51
35	Homologous and Heterologous Covid-19 Booster Vaccinations <i>New England Journal of Medicine</i> , <b>2022</b> ,	59.2	50
34	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 221-228	8	47
33	Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 344-352	8	36
32	Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study. Journal of Infectious Diseases, <b>2016</b> , 213, 335-42	7	34
31	Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	23
30	Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. <i>Lancet HIV,the</i> , <b>2021</b> , 8, e87-e95	7.8	22
29	Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , <b>2020</b>	2.8	21
28	Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128857	3.7	21
27	Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. <i>Journal of the International AIDS Society</i> , <b>2020</b> , 23, e25634	5.4	20
26	Impact of Pill Sharing on Drug Resistance Due to a Wide-Scale Oral Prep Intervention in Generalized Epidemics. <i>Journal of AIDS &amp; Clinical Research</i> , <b>2012</b> , Suppl 5,	1	15
25	Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. <i>Lancet HIV,the</i> , <b>2019</b> , 6, e475-e482	7.8	13

## (2021-2012)

24	An alternative method for quantifying coronary artery calcification: the multi-ethnic study of atherosclerosis (MESA). <i>BMC Medical Imaging</i> , <b>2012</b> , 12, 14	2.9	13
23	Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2017</b> , 76, 330-337	3.1	12
22	Oral and injectable contraceptive use and HIV acquisition risk among women in four African countries: a secondary analysis of data from a microbicide trial. <i>Contraception</i> , <b>2016</b> , 93, 25-31	2.5	11
21	Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2018</b> , 77, e8-e10	3.1	9
20	High incidence is not high exposure: what proportion of prevention trial participants are exposed to HIV?. <i>PLoS ONE</i> , <b>2015</b> , 10, e0115528	3.7	7
19	Elevated Risk of Bacterial Vaginosis Among Users of the Copper Intrauterine Device: A Prospective Longitudinal Cohort Study. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 513-520	11.6	6
18	Implementation of a prospective pregnancy registry for antiretroviral based HIV prevention trials. <i>HIV Clinical Trials</i> , <b>2018</b> , 19, 8-14		5
17	Estimating effectiveness in HIV prevention trials with a Bayesian hierarchical compound Poisson frailty model. <i>Statistics in Medicine</i> , <b>2016</b> , 35, 2609-34	2.3	4
16	The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence. <i>AIDS and Behavior</i> , <b>2021</b> , 25, 4169-4179	4.3	3
15	Prevalent HPV infection increases the risk of HIV acquisition in African women: advancing the argument for HPV immunization. <i>Aids</i> , <b>2021</b> ,	3.5	3
14	Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial. <i>AIDS and Behavior</i> , <b>2021</b> , 25, 2430-2440	4.3	3
13	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. <i>Viruses</i> , <b>2021</b> , 13,	6.2	3
12	Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial. <i>Trials</i> , <b>2021</b> , 22, 661	2.8	3
11	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofac124	1	3
10	Preventive Misconception and Risk Behaviors in a Multinational HIV Prevention Trial. <i>AJOB Empirical Bioethics</i> , <b>2019</b> , 10, 79-87	3	2
9	Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity <i>JAMA Network Open</i> , <b>2022</b> , 5, e214	2 <del>79</del> 6	2
8	Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities. <i>Aids</i> , <b>2020</b> , 34, 559-567	3.5	2
7	Spatially Weighted Coronary Artery Calcium Score and Coronary Heart Disease Events in the Multi-Ethnic Study of Atherosclerosis. <i>Circulation: Cardiovascular Imaging</i> , <b>2021</b> , 14, e011981	3.9	2

6	Comparison of Racial, Ethnic, and Geographic Location Diversity of Participants Enrolled in Clinic-Based vs 2 Remote COVID-19 Clinical Trials <i>JAMA Network Open</i> , <b>2022</b> , 5, e2148325	10.4	2
5	Estimating the effectiveness in HIV prevention trials by incorporating the exposure process: application to HPTN 035 data. <i>Biometrics</i> , <b>2014</b> , 70, 745-53	1.8	1
4	Risk of SARS-CoV-2 acquisition is associated with individual exposure but not community-level transmission <i>Journal of Infectious Diseases</i> , <b>2022</b> ,	7	1
3	Brief Report: Anal Intercourse, HIV-1 Risk, and Efficacy in a Trial of a Dapivirine Vaginal Ring for HIV-1 Prevention. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2020</b> , 83, 197-201	3.1	1
2	Designing HIV Vaccine Efficacy Trials in the Context of Highly Effective Non-vaccine Prevention Modalities. <i>Statistics in Biosciences</i> , <b>2020</b> , 12, 468-494	1.5	1
1	Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention. <i>AIDS and Behavior</i> , <b>2021</b> , 25, 2801-2814	4.3	1